MREO - Baird starts Mereo at outperform sees alvelestat as underappreciated
2024-06-13 16:48:30 ET
More on Mereo BioPharma Group
- Mereo BioPharma's Pipeline Promise Vs. Valuation And Market Realities
- Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
- Mereo BioPharma Group GAAP EPS of -$0.04
- Seeking Alpha’s Quant Rating on Mereo BioPharma Group
- Historical earnings data for Mereo BioPharma Group